Artificial Intelligence: Applications in Pharmacovigilance Signal Management
Pharmaceutical Medicine · 2025-05 · 39 (3) · 183-198
DOI: 10.1007/s40290-025-00561-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutical Medicine, online erschienen am 21.04.2025. Verfasst von Jeffrey Warner und 2 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: Pharmacovigilance, Artificial Intelligence, Drug-Related Side Effects and Adverse Reactions, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Pharmacovigilance is the science of collection, detection, and assessment of adverse events associated with pharmaceutical products for the ongoing monitoring and understanding of those products' safety profiles. Part of this process, signal management, encompasses the activities of signal detection, signal validation/confirmation, signal evaluation, and ultimately, final assessment as to whether a safety signal constitutes a new causal adverse drug reaction. Artificial intelligence is a group of technologies including machine learning and natural language processing that are revolutionizing multiple industries through intelligent automation. Here, we present a critical evaluation of studies leveraging artificial intelligence in signal management to characterize the benefits and limitations of the technology, the level of transparency, and our perspective on best practices for the future. To this end, PubMed and Embase were searched cumulatively for terms pertaining to signal management and artificial intelligence, machine learning, or natural language processing. Information pertaining to the artificial intelligence model used, hyperparameter settings, training/testing data, performance, feature analysis, and more was extracted from included articles. Common signal detection methods included k-means, random forest, and gradient boosting machine. Machine learning algorithms generally outperformed traditional frequentist or Bayesian measures of disproportionality per various metrics, showing the potential utility of advanced machine learning technologies in signal detection. In signal validation and evaluation, natural language processing was typically applied. Overall, methodological transparency was mixed and only some studies leveraged "gold standard" publicly available positive and negative control datasets. Overall, innovation in pharmacovigilance signal management is being driven by machine learning and natural language processing models, particularly in signal detection, in part because of high-performing bagging methods such as random forest and gradient boosting machine. These technologies may be well poised to accelerate progress in this field when used transparently and ethically. Future research is needed to assess the applicability of these techniques across various therapeutic areas and drug classes in the broader pharmaceutical industry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Eli Lilly and Company, Indianapolis, IN, USA.
- Eli Lilly and Company, Indianapolis, IN, USA. albera_claudia@lilly.com.
ORCID-Profile: Jeffrey Warner, Anaclara Prada Jardim
Zitieren
APA
Warner, J., Prada Jardim, A., & Albera, C. (2025). Artificial Intelligence: Applications in Pharmacovigilance Signal Management. Pharmaceutical Medicine, 39(3), 183-198. https://doi.org/10.1007/s40290-025-00561-2
Vancouver
Warner J, Prada Jardim A, Albera C. Artificial Intelligence: Applications in Pharmacovigilance Signal Management. Pharmaceutical Medicine. 2025;39(3):183-198. doi:10.1007/s40290-025-00561-2
BibTeX
@article{Warner2025,
author = {Warner, Jeffrey and Prada Jardim, Anaclara and Albera, Claudia},
title = {Artificial Intelligence: Applications in Pharmacovigilance Signal Management},
journal = {Pharmaceutical Medicine},
year = {2025},
volume = {39},
number = {3},
pages = {183--198},
doi = {10.1007/s40290-025-00561-2}
}
EUVIMED